Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Rush Street Interactive Inc (RSI) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

Rush Street Interactive (RSI) trades at $24.53, down 0.77% on the day, amid mixed technical signals with a bearish overall trend but oversold oscillators. The company reported strong Q2 2026 results with record revenue of $393.8 million and raised full-year guidance, though net margins remain thin at 2.33%. Analyst sentiment remains bullish with 77% buy ratings and a $34.75 consensus target.

RSI shows promising revenue growth and institutional interest but faces valuation concerns with a high P/E of 81.13. The stock offers significant upside to analyst targets but requires careful monitoring of margin expansion and competitive pressures in the online gambling sector.